BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2017 Earnings Results

Biocryst Pharmaceuticals Misses on EPS, Stock Down 10.59%

The earnings report reflects ongoing challenges for Biocryst Pharmaceuticals, particularly in terms of profitability, as indicated by the negative EPS. The stock reacted negatively, dropping 10.59%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future performance without clear direction from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.19	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to advancing clinical programs.

Management did not provide specific revenue guidance for the upcoming quarters.

The focus remains on ongoing clinical trials and product development.

Biocryst Pharmaceuticals Misses on EPS, Stock Down 10.59%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

Biocryst Pharmaceuticals Misses on EPS, Stock Down 10.59%

Key numbers

Management commentary